These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30003670)

  • 41. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
    Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
    Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin.
    Pettus J; McNabb B; Eckel RH; Skyler JS; Dhalla A; Guan S; Jochelson P; Belardinelli L; Henry RH
    Diabetes Obes Metab; 2016 May; 18(5):463-74. PubMed ID: 26749407
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
    Fonseca V; Gill J; Zhou R; Leahy J
    Diabetes Obes Metab; 2011 Sep; 13(9):814-22. PubMed ID: 21481127
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial.
    Chon S; Rhee SY; Ahn KJ; Baik SH; Park Y; Nam MS; Lee KW; Yoo SJ; Koh G; Lee DH; Kim YS; Woo JT;
    Diabetes Obes Metab; 2018 May; 20(5):1121-1130. PubMed ID: 29272062
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.
    Azar ST; Echtay A; Wan Bebakar WM; Al Araj S; Berrah A; Omar M; Mutha A; Tornøe K; Kaltoft MS; Shehadeh N
    Diabetes Obes Metab; 2016 Oct; 18(10):1025-33. PubMed ID: 27376711
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
    Vilsbøll T; Rosenstock J; Yki-Järvinen H; Cefalu WT; Chen Y; Luo E; Musser B; Andryuk PJ; Ling Y; Kaufman KD; Amatruda JM; Engel SS; Katz L
    Diabetes Obes Metab; 2010 Feb; 12(2):167-77. PubMed ID: 20092585
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative effectiveness of sitagliptin vs sulphonylureas in older people.
    Sharma M; Nazareth I; Petersen I
    Age Ageing; 2019 Sep; 48(5):725-732. PubMed ID: 31250890
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population-based cohort study.
    Islam N; Reynier P; Douros A; Yu OHY; Filion KB
    Diabetes Obes Metab; 2023 Jun; 25(6):1523-1533. PubMed ID: 36722703
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metformin monotherapy for adults with type 2 diabetes mellitus.
    Gnesin F; Thuesen ACB; Kähler LKA; Madsbad S; Hemmingsen B
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD012906. PubMed ID: 32501595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea.
    Weissman PN; Carr MC; Ye J; Cirkel DT; Stewart M; Perry C; Pratley R
    Diabetologia; 2014 Dec; 57(12):2475-84. PubMed ID: 25208756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality.
    Eriksson JW; Bodegard J; Nathanson D; Thuresson M; Nyström T; Norhammar A
    Diabetes Res Clin Pract; 2016 Jul; 117():39-47. PubMed ID: 27329021
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.
    Gulliford M; Latinovic R
    Diabetes Metab Res Rev; 2004; 20(3):239-45. PubMed ID: 15133756
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Different clinical prognostic factors are associated with improved glycaemic control: findings from MARCH randomized trial.
    Han J; Yu H; Tu Y; Pang J; Liu F; Bao Y; Yang W; Jia W
    Diabet Med; 2017 Apr; 34(4):490-499. PubMed ID: 27151271
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
    D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
    Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
    Ridderstråle M; Rosenstock J; Andersen KR; Woerle HJ; Salsali A;
    Diabetes Obes Metab; 2018 Dec; 20(12):2768-2777. PubMed ID: 29961998
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.
    Anyanwagu U; Mamza J; Mehta R; Donnelly R; Idris I
    Heart; 2016 Oct; 102(19):1581-7. PubMed ID: 27217068
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study.
    Alvarez Guisasola F; Tofé Povedano S; Krishnarajah G; Lyu R; Mavros P; Yin D
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():25-32. PubMed ID: 18435671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.